Search Results Heading

MBRLSearchResults

mbrl.module.common.modules.added.book.to.shelf
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
    Done
    Filters
    Reset
  • Discipline
      Discipline
      Clear All
      Discipline
  • Is Peer Reviewed
      Is Peer Reviewed
      Clear All
      Is Peer Reviewed
  • Item Type
      Item Type
      Clear All
      Item Type
  • Subject
      Subject
      Clear All
      Subject
  • Year
      Year
      Clear All
      From:
      -
      To:
  • More Filters
      More Filters
      Clear All
      More Filters
      Source
    • Language
515,799 result(s) for "Royalties"
Sort by:
What’s next for Andrew after losing his royal title?
After years of damaging headlines over his ties to Jeffrey Epstein, Andrew was stripped of his royal title. The Post's Karla Adam breaks down what this means for King Charles III's brother.
UNIVERZITY POTREBUJÚ PODPORU SILNÝCH INVESTOROV
Obe skupiny chcú spolupracovať priamo so samotnou univerzitnou spin-off spoločnosťou, lebo majú záujem do nej investovaťa zhodnotiť kapitál, avšak majú iné formálne nároky na spoluprácu\" povedal Michal Nešpor, ktorýje zodpovedný za vedenie investičného fondu CB Investment Management, dcérskej spoločnosti investičnej platformy Crowdberry. Tu je ale dôležité správne nastaviť systém vzájomnej spolupráce medzi pôvodcom vynálezu a univerzitou samotnou pred tým, ako založí firmu na pôde univerzity. „Podľa môjho názoru to funguje vtedy, keď univerzita nastaví jednoznačné pravidlá, procesy a právny rámec, na základe ktorých vedec v danej univerzite vie, za akých podmienok môže určitú technológiu či vynález komercializovat' \" vysvetlil Nešpor. Záujem o investovanie podľa jeho slov medziročne stúpa. „Dokonca by som povedal, že za posledný rok dramaticky rastie. ODPORÚČANIA PRE UNIVERZITY, AK SA CHCÚ UCHÁDZAŤ O KAPITAL OD INVESTOROV * Pred oslovením investora je potrebné mať vyriešené práva na duševné vlastníctvo. * Pred predstavením spin-off spoločnosti investorovi je samozrejmosťou dôkladná príprava biznis plánu a financovania. * Univerzitné spin-off spoločnosti musia mať kvalitný tím zložený nielen z vedcov, ale aj odborníkov na obchod a marketing. * Spin-off spoločnosti musia pôsobiť na trhu, ktorý je dostatočne zaujímavý pre väčších investorov. * Investorov vo vyspelých krajinách lákajú spin-off spoločnosti, kde nemá univerzita väčšinový podiel. * Univerzita by mala s investormi podpisovať takzvané „royality zmluvy\".
Geographic Dispersion of Economic Shocks: Evidence from the Fracking Revolution
We track the geographic and temporal propagation of local economic shocks from new oil and gas production generated by hydrofracturing. Each million dollars of new production produces $80,000 in wage income and $132,000 in royalty and business income within a county. Within 100 miles, one million dollars of new production generates $257,000 in wages and $286,000 in royalty and business income. Roughly two-thirds of the wage income increase persists for two years. Assuming no general equilibrium effects, new extraction increased aggregate US employment by as many as 640,000, and decreased the unemployment rate by 0.43 during the Great Recession.
E-221 Simply the (B)EST : what the neurointerventionalist needs to know about (bleomycin) electrosclerotherapy for vascular anomalies
IntroductionVascular anomalies (VAs) encompass a diverse group of conditions that require specialized multidisciplinary management. Bleomycin electrosclerotherapy ([B]EST) integrates electroporation with intralesional bleomycin administration, enhancing drug uptake while minimizing damage to surrounding tissues. Despite its potential, the role of (B)EST in managing VAs remains understudied. Objective: This systematic review evaluates the efficacy, safety, and procedural protocols of (B)EST in treating VAs.MethodsA systematic review was conducted following PRISMA guidelines, searching PubMed, Web of Science, and Scopus databases. Inclusion criteria consisted of peer-reviewed original studies evaluating (B)EST for VAs, excluding reviews, editorials, and animal studies.ResultsOf 1,228 identified records, 14 studies met inclusion criteria. These were published between 2012 and 2025, predominantly from Europe (12/14). In total, 543 patients were included: 422 with vascular malformations and 121 with vascular tumors (Kaposi sarcoma, angiosarcoma). (B)EST was primarily employed in low-flow malformations, achieving total obliteration rates between 15.05% and 62.8%, and lesion size reductions ranging from 66.7% to 100%. In vascular tumors, complete responses ranged from 65% to 100%. Most studies adhered to current procedural guidelines, using bleomycin doses ranging from 200 to 10,000 IU per session. Adverse effects were predominantly local, mild, and self-limiting, with ulcerations primarily noted in vascular tumors.Conclusion(B)EST demonstrates promising results for the treatment of VAs, especially venous and lymphatic malformations. Although findings support its efficacy and safety, procedural heterogeneity and the need for long-term outcome data warrant further investigation. Developing optimized, tailored protocols for specific VA subtypes and clinical presentations is crucial to clearly define the role of (B)EST in VA management.DisclosuresJ. Ognard: 6; C; J.O. received research grants from SFNR, GIRCI-GO, INNOVEO-Chu De Brest, Medtronic, Phenox, Institut Servier, Philippe Foundation, Philips, and receives consulting fees from Balt. A. Alateya: None. G. El Hajj: None. Z. Alateya: None. S. Ghozy: None. R. Kadirvel: 1; C; R.K. received research support from Cerenovus Inc, Medtronic, Endovascular Engineering, Frontier Bio, Sensome Inc, Endomimetics, Ancure LLC, Neurogami Medical, MIVI Biosciences, Monarch Biosciences., RK received research support from Stryker, Conway Medical, Piraeus Medical, and Bionaut Labs. D. Kallmes: 6; C; D.F.K. holds equity in Nested Knowledge, Superior Medical Editors, and Conway Medical, Marblehead Medical and Piraeus Medical. He receives grant support from MicroVention, Medtronic, Balt, and Insera Therapeutics; has served on the Data Safety Monitoring Board for Vesalio; and received royalties from Medtronic. W. Brinjikji: 6; C; W.B. holds equity in Nested Knowledge, Superior Medical Editors, Piraeus Medical, Sonoris Medical, and MIVI Neurovascular. He receives royalties from Medtronic and Balloon Guide Catheter Technology., He receives consulting fees from Medtronic, Stryker, Imperative Care, Microvention, MIVI Neurovascular, Cerenovus, Asahi, and Balt., He serves in a leadership or fiduciary role for MIVI Neurovascular, Marblehead Medical LLC, Interventional Neuroradiology (Editor in Chief), Piraeus Medical, and WFITN.
Índices de desenvolvimento municipais e royalties do petróleo: uma abordagem multivariada de comparação de perfis entre municípios que recebem ou não royalties pelo petróleo produzido
O setor petrolífero brasileiro vem obtendo altos índices de crescimento e em 2006 foi anunciada a autossuficiência em Petróleo. De 1991 a 2011, a Petrobrás teve um crescimento de 164% nas suas reservas. Nesse mesmo período, o Brasil aprovou a lei do petróleo (Lei No 9.478), estabelecendo novos critérios para a transferência de royalties do petróleo para os municípios brasileiros. Sendo assim, este trabalho tem como objetivo verificar se os pagamentos de royalties aos municípios, de alguma forma, têm contribuído para melhorar os seus indicadores sociais. Portanto, foi feita uma comparação entre municípios de mesmo porte populacional que recebem ou não royalties. Para a comparação foram utilizadas as variáveis: IDHM, IFDM, IDEB e incidência de pobreza. Utilizou-se das técnicas de Análise de Perfis, Análise de Agrupamento e Análise Fatorial com objetivo de verificar se existe diferença entre as matrizes de dados referentes aos municípios que recebem e os que não recebem royalties.
Optimal patent licensing: from three to two part tariffs
We study the licensing of a cost-reducing innovation in a Cournot oligopoly where an outside innovator uses three part tariffs that are combinations of upfront fees, per unit royalties and ad valorem royalties. Under general demand, the maximum possible licensing revenue under three part tariffs can be always attained by a policy that uses at most two of the three components. For relatively significant innovations, there exists an optimal policy consisting of a per unit royalty and upfront fee and a continuum of other optimal policies that are three part tariffs whose all components are positive. Completely characterizing optimal policies under linear demand, we show that for oligopolies with four or more firms: (i) pure upfront fees are optimal for insignificant innovations; (ii) for intermediate and significant innovations: (a) there is a continuum of optimal policies which always includes a two part tariff with a unit royalty and upfront fee and (b) a two part tariff with an ad valorem royalty and fee or a two part royalty can be optimal for some, but not all parametric configurations.